Table 1: Results of immunohistochemistry staining’s from different samples.
|
axillary
lymph node FNAB |
axillary
lymph node CB |
surgical
specimen |
||
|
no immunohistochemistry was assessed |
CK7 |
+ |
CK7 |
+ |
|
pan-CK |
+ |
pan-CK |
+ |
|
|
S100 |
+ |
S100 |
- |
|
|
BCA225 |
+/- |
BCA225 |
+/- |
|
|
CK20 |
+/- |
CK20 |
- |
|
|
ER |
+/- |
ER |
- |
|
|
PR |
+/- |
PR |
- |
|
|
GCDFP-15 |
- |
GCDFP-15 |
- |
|
|
CA19-9 |
- |
CA19-9 |
- |
|
|
HMB45 |
- |
CA125 |
+ |
|
|
LCA |
- |
Ber-EP4 |
- |
|
|
|
|
CDX2 |
- |
|
FNAB:
Fine-Needle Aspiration Biopsy, CB: Core Biopsy,
+ : Positive, -: Negative, +/-: Partial or focal positivity, CK7: Cytokeratin
7, pan-CK: Pan-Cytokeratin, CK20: Cytokeratin 20, S100: S100 protein, BCA225: Breast
Carcinoma - Associated Glycoprotein 225, ER: Estrogen Receptor, PR: Progesterone
Receptor, GCDFP-15: Gross Cystic Disease Fluid Protein-15, TTF1: Thyroid
Transcription Factor 1, CEA: Carcinoembryonic
Antigen, CA19-9: Carbohydrate Antigen 19-9, CA125: Carbohydrate Antigen 125,
HMB45: Human Melanoma Black 45, LCA: Leukocyte Common Antigen, CDX2: Caudal Related Homeobox
Transcription Factor 2, Ber-EP4: Mouse
Monoclonal Anti-Epcam/Cd326 Antibody.